Cargando…

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3

Receptor tyrosine kinases of the HER-family are involved in the development and progression of multiple epithelial tumors, and have consequently become widely used targets for new anti-cancer therapies. Trastuzumab, an antibody against HER2, has shown potent growth inhibitory effects on HER2 overexp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebbing, Eva A., Medema, Jan Paul, Damhofer, Helene, Meijer, Sybren L., Krishnadath, Kausilia K., van Berge Henegouwen, Mark I., Bijlsma, Maarten F., van Laarhoven, Hanneke W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891117/ https://www.ncbi.nlm.nih.gov/pubmed/26863569 http://dx.doi.org/10.18632/oncotarget.7200

Ejemplares similares

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract
por: Damhofer, Helene, et al.
Publicado: (2015)

The dynamics of HER2 status in esophageal adenocarcinoma
por: Creemers, Aafke, et al.
Publicado: (2018)

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas
por: Creemers, Aafke, et al.
Publicado: (2018)

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
por: Steins, Anne, et al.
Publicado: (2017)

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma
por: Ebbing, Eva A., et al.
Publicado: (2019)

Chemoradiation induces epithelial‐to‐mesenchymal transition in esophageal adenocarcinoma
por: Steins, Anne, et al.
Publicado: (2019)

Stromal SPOCK1 supports invasive pancreatic cancer growth
por: Veenstra, Veronique L., et al.
Publicado: (2017)

Patched-2 functions to limit Patched-1 deficient skin cancer growth
por: Veenstra, Veronique L., et al.
Publicado: (2018)

Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery
por: Milano, Francesca, et al.
Publicado: (2010)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma
por: Hurrell, Tracey, et al.
Publicado: (2013)

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
por: Mota, Jose Mauricio, et al.
Publicado: (2017)

Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas
por: Soeratram, Tanya TD, et al.
Publicado: (2021)

The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth
por: Manoukian, Paul, et al.
Publicado: (2021)

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol
por: Noordman, Bo Jan, et al.
Publicado: (2015)

ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy
por: Veenstra, V. L., et al.
Publicado: (2018)

ADAM10 and ADAM17: New Players in Trastuzumab Resistance
por: Duffy, Michael J., et al.
Publicado: (2014)

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2004)

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2014)

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer
por: ten Hoorn, Sanne, et al.
Publicado: (2022)

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
por: Kang, Jeffrey C, et al.
Publicado: (2014)

Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models
por: Li, Shulin, et al.
Publicado: (2022)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer
por: Gijsen, M, et al.
Publicado: (2010)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

Genetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing Cholangitis
por: Timmer, Margriet R., et al.
Publicado: (2016)

A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
por: Al-Akhrass, Hussein, et al.
Publicado: (2021)

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3
por: Chakrabarty, Anindita, et al.
Publicado: (2010)

Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer
por: Dings, Mark P.G., et al.
Publicado: (2022)

Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer
por: Veenstra, Veronique L., et al.
Publicado: (2018)

Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies
por: Hoefnagel, Sanne J. M., et al.
Publicado: (2022)

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma
por: Liu, Dajia, et al.
Publicado: (2020)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines
por: Momeny, Majid, et al.
Publicado: (2015)

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
por: Dijksterhuis, Willemieke P. M., et al.
Publicado: (2020)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
por: Kim, Sangmin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hrdbvk0o17nm62ngd5ji5ibs02